Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 6, 2014, Pages 1155-1177

  Zordoky, Beshay N M ^a   Robertson, Ian M ^a   Dyck, Jason R B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiovascular disease; Resveratrol

Indexed keywords

CARDIOVASCULAR AGENTS; RESVERATROL; STILBENES;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG EFFECTS; HEART RATE; HUMANS; VASODILATION;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HEART RATE; HUMANS; STILBENES; VASODILATION;

EID: 84937532657     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.10.016     Document Type: Review

References (323)

1. WHO (in). http://www.who.int/cardiovascular_diseases/en/.
2. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., Dai S., Ford E.S., Fox C.S., Franco S., Fullerton H.J., Gillespie C., Hailpern S.M., Heit J.A., Howard V.J., Huffman M.D., Judd S.E., Kissela B.M., Kittner S.J., Lackland D.T., Lichtman J.H., Lisabeth L.D., Mackey R.H., Magid D.J., Marcus G.M., Marelli A., Matchar D.B., McGuire D.K., Mohler E.R., Moy C.S., Mussolino M.E., Neumar R.W., Nichol G., Pandey D.K., Paynter N.P., Reeves M.J., Sorlie P.D., Stein J., Towfighi A., Turan T.N., Virani S.S., Wong N.D., Woo D., Turner M.B., C.American Heart Association Statistics, S.Stroke Statistics Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:399-410.
3. Scalbert A., Williamson G. Dietary intake and bioavailability of polyphenols. J. Nutr. 2000, 130:2073S-2085S.
4. Dolinsky V.W., Dyck J.R. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim. Biophys. Acta 2011, 1812:1477-1489.
5. Tome-Carneiro J., Gonzalvez M., Larrosa M., Yanez-Gascon M.J., Garcia-Almagro F.J., Ruiz-Ros J.A., Tomas-Barberan F.A., Garcia-Conesa M.T., Espin J.C. Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Ann. N. Y. Acad. Sci. 2013, 1290:37-51.
6. Mikulski D., Gorniak R., Molski M. A theoretical study of the structure-radical scavenging activity of trans-resveratrol analogues and cis-resveratrol in gas phase and water environment. Eur. J. Med. Chem. 2010, 45:1015-1027.
7. Basly J.P., Marre-Fournier F., Le Bail J.C., Habrioux G., Chulia A.J. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci. 2000, 66:769-777.
8. Camont L., Cottart C.H., Rhayem Y., Nivet-Antoine V., Djelidi R., Collin F., Beaudeux J.L., Bonnefont-Rousselot D. Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Anal. Chim. Acta 2009, 634:121-128.
9. Catalgol B., Batirel S., Taga Y., Ozer N.K. Resveratrol: French paradox revisited. Front. Pharmacol. 2012, 3:141.
10. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339:1523-1526.
11. Agatonovic-Kustrin S., Hettiarachchi C.G., Morton D.W., Razic S. Analysis of phenolics in wine by high performance thin-layer chromatography with gradient elution and high resolution plate imaging. J. Pharm. Biomed. Anal. 2014, 102C:93-99.
12. Cottart C.H., Nivet-Antoine V., Beaudeux J.L. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol. Nutr. Food Res. 2014, 58:7-21.
13. Block G., Jensen C.D., Norkus E.P., Dalvi T.B., Wong L.G., McManus J.F., Hudes M.L. Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study. Nutr. J. 2007, 6:30.
14. Bertelli A.A.E., Giovannini L., Giannessi D., Migliori M., Bernini W., Fregoni M., Bertelli A. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tissue React. 1995, 17:1-3.
15. Li H., Xia N., Forstermann U. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 2012, 26:102-110.
16. Tome-Carneiro J., Larrosa M., Gonzalez-Sarrias A., Tomas-Barberan F.A., Garcia-Conesa M.T., Espin J.C. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 2013, 19:6064-6093.
17. Aronow W.S., Fleg J.L., Pepine C.J., Artinian N.T., Bakris G., Brown A.S., Ferdinand K.C., Ann Forciea M., Frishman W.H., Jaigobin C., Kostis J.B., Mancia G., Oparil S., Ortiz E., Reisin E., Rich M.W., Schocken D.D., Weber M.A., Wesley D.J., Harrington R.A., Bates E.R., Bhatt D.L., Bridges C.R., Eisenberg M.J., Ferrari V.A., Fisher J.D., Gardner T.J., Gentile F., Gilson M.F., Hlatky M.A., Jacobs A.K., Kaul S., Moliterno D.J., Mukherjee D., Rosenson R.S., Stein J.H., Weitz H.H. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J. Am. Soc. Hypertens. 2011, 5:259-352.
18. Whelton P.K., He J., Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J. Hum. Hypertens. 2004, 18:545-551.
19. Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA 2014, 311:2216-2224.
20. Susic D., Frohlich E.D. Hypertensive cardiovascular and renal disease and target organ damage: lessons from animal models. Cardiorenal. Med. 2011, 1:139-146.
21. Wu J.M., Hsieh T.C. Resveratrol: a cardioprotective substance. Ann. N. Y. Acad. Sci. 2011, 1215:16-21.
22. Mannari C., Bertelli A.A., Stiaccini G., Giovannini L. Wine, sirtuins and nephroprotection: not only resveratrol. Med. Hypotheses 2010, 75:636-638.
23. Pallas M., Porquet D., Vicente A., Sanfeliu C. Resveratrol: new avenues for a natural compound in neuroprotection. Curr. Pharm. Des. 2013, 19:6726-6731.
24. Bola C., Bartlett H., Eperjesi F. Resveratrol and the eye: activity and molecular mechanisms. Graefes Arch. Clin. Exp. Ophthalmol. 2014, 252:699-713.
25. Dolinsky V.W., Chakrabarti S., Pereira T.J., Oka T., Levasseur J., Beker D., Zordoky B.N., Morton J.S., Nagendran J., Lopaschuk G.D., Davidge S.T., Dyck J.R. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim. Biophys. Acta 2013, 1832:1723-1733.
26. Bhatt S.R., Lokhandwala M.F., Banday A.A. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur. J. Pharmacol. 2011, 667:258-264.
27. Cao X., Luo T., Luo X., Tang Z. Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice. Hypertens. Res. 2014, 37(9):803-810.
28. Toklu H.Z., Sehirli O., Ersahin M., Suleymanoglu S., Yiginer O., Emekli-Alturfan E., Yarat A., Yegen B.C., Sener G. Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats. J. Pharm. Pharmacol. 2010, 62:1784-1793.
29. Liu Z., Song Y., Zhang X., Zhang W., Mao W., Wang W., Cui W., Jia X., Li N., Han C., Liu C. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin. Exp. Pharmacol. Physiol. 2005, 32:1049-1054.
30. Dolinsky V.W., Chan A.Y., Robillard Frayne I., Light P.E., Des Rosiers C., Dyck J.R. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009, 119:1643-1652.
31. Thandapilly S.J., Louis X.L., Behbahani J., Movahed A., Yu L., Fandrich R., Zhang S., Kardami E., Anderson H.D., Netticadan T. Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats. Hypertens. Res. 2013, 36:866-872.
32. Thandapilly S.J., Wojciechowski P., Behbahani J., Louis X.L., Yu L., Juric D., Kopilas M.A., Anderson H.D., Netticadan T. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am. J. Hypertens. 2010, 23:192-196.
33. Chan V., Fenning A., Iyer A., Hoey A., Brown L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr. Pharm. Biotechnol. 2011, 12:429-436.
34. Rivera L., Moron R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77:1053-1063.
35. Akar F., Uludag O., Aydin A., Aytekin Y.A., Elbeg S., Tuzcu M., Sahin K. High-fructose corn syrup causes vascular dysfunction associated with metabolic disturbance in rats: protective effect of resveratrol. Food Chem. Toxicol. 2012, 50:2135-2141.
36. Miatello R., Vazquez M., Renna N., Cruzado M., Zumino A.P., Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am. J. Hypertens. 2005, 18:864-870.
37. Mizutani K., Ikeda K., Kawai Y., Yamori Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol. (Tokyo) 2000, 46:78-83.
38. Aubin M.C., Lajoie C., Clement R., Gosselin H., Calderone A., Perrault L.P. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J. Pharmacol. Exp. Ther. 2008, 325:961-968.
39. Behbahani J., Thandapilly S.J., Louis X.L., Huang Y., Shao Z., Kopilas M.A., Wojciechowski P., Netticadan T., Anderson H.D. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am. J. Hypertens. 2010, 23:1273-1278.
40. Rush J.W., Quadrilatero J., Levy A.S., Ford R.J. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp. Biol. Med. (Maywood) 2007, 232:814-822.
41. Soylemez S., Sepici A., Akar F. Resveratrol supplementation gender independently improves endothelial reactivity and suppresses superoxide production in healthy rats. Cardiovasc. Drugs Ther. 2009, 23:449-458.
42. Hadi H.A., Carr C.S., Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc. Health Risk Manag. 2005, 1:183-198.
43. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E., Jamieson H.A., Zhang Y., Dunn S.R., Sharma K., Pleshko N., Woollett L.A., Csiszar A., Ikeno Y., Le Couteur D., Elliott P.J., Becker K.G., Navas P., Ingram D.K., Wolf N.S., Ungvari Z., Sinclair D.A., de Cabo R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8:157-168.
44. Akar F., Pektas M.B., Tufan C., Soylemez S., Sepici A., Ulus A.T., Gokalp B., Ozturk K., Surucu H.S. Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovasc. Drugs Ther. 2011, 25:119-131.
45. Hamza S.M., Dyck J.R. Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol. Front Physiol. 2014, 5:292.
46. Goh S.S., Woodman O.L., Pepe S., Cao A.H., Qin C., Ritchie R.H. The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antioxid. Redox Signal. 2007, 9:101-113.
47. Xu Q., Hao X., Yang Q., Si L. Resveratrol prevents hyperglycemia-induced endothelial dysfunction via activation of adenosine monophosphate-activated protein kinase. Biochem. Biophys. Res. Commun. 2009, 388:389-394.
48. Wallerath T., Deckert G., Ternes T., Anderson H., Li H., Witte K., Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002, 106:1652-1658.
49. Leikert J.F., Rathel T.R., Wohlfart P., Cheynier V., Vollmar A.M., Dirsch V.M. Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation 2002, 106:1614-1617.
50. Calvert J.W., Lefer D.J. Myocardial protection by nitrite. Cardiovasc. Res. 2009, 83:195-203.
51. Arunachalam G., Yao H., Sundar I.K., Caito S., Rahman I. SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem. Biophys. Res. Commun. 2010, 393:66-72.
52. Csiszar A., Labinskyy N., Pinto J.T., Ballabh P., Zhang H., Losonczy G., Pearson K., de Cabo R., Pacher P., Zhang C., Ungvari Z. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H13-H20.
53. Nagendran J., Waller T.J., Dyck J.R. AMPK signalling and the control of substrate use in the heart. Mol. Cell. Endocrinol. 2013, 366:180-193.
54. Chen Z.P., Mitchelhill K.I., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., Power D.A., Ortiz de Montellano P.R., Kemp B.E. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999, 443:285-289.
55. Carrizzo A., Puca A., Damato A., Marino M., Franco E., Pompeo F., Traficante A., Civitillo F., Santini L., Trimarco V., Vecchione C. Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension 2013, 62:359-366.
56. Gordish K.L., Beierwaltes W.H. Resveratrol induces acute endothelium-dependent renal vasodilation mediated through nitric oxide and reactive oxygen species scavenging. Am. J. Physiol. Renal Physiol. 2014, 306:F542-F550.
57. Carrizzo A., Forte M., Damato A., Trimarco V., Salzano F., Bartolo M., Maciag A., Puca A.A., Vecchione C. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem. Toxicol. 2013, 61:215-226.
58. Kao C.L., Chen L.K., Chang Y.L., Yung M.C., Hsu C.C., Chen Y.C., Lo W.L., Chen S.J., Ku H.H., Hwang S.J. Resveratrol protects human endothelium from H(2)O(2)-induced oxidative stress and senescence via SirT1 activation. J. Atheroscler. Thromb. 2010, 17:970-979.
59. Price N.L., Gomes A.P., Ling A.J., Duarte F.V., Martin-Montalvo A., North B.J., Agarwal B., Ye L., Ramadori G., Teodoro J.S., Hubbard B.P., Varela A.T., Davis J.G., Varamini B., Hafner A., Moaddel R., Rolo A.P., Coppari R., Palmeira C.M., de Cabo R., Baur J.A., Sinclair D.A. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012, 15:675-690.
60. Novakovic A., Gojkovic-Bukarica L., Peric M., Nezic D., Djukanovic B., Markovic-Lipkovski J., Heinle H. The mechanism of endothelium-independent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery. J. Pharmacol. Sci. 2006, 101:85-90.
61. Zou J.G., Wang Z.R., Huang Y.Z., Cao K.J., Wu J.M. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int. J. Mol. Med. 2003, 11:317-320.
62. Liu J.C., Chen J.J., Chan P., Cheng C.F., Cheng T.H. Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension 2003, 42:1198-1205.
63. McCalley A.E., Kaja S., Payne A.J., Koulen P. Resveratrol and calcium signaling: molecular mechanisms and clinical relevance. Molecules 2014, 19:7327-7340.
64. Campos-Toimil M., Elies J., Alvarez E., Verde I., Orallo F. Effects of trans- and cis-resveratrol on Ca2+ handling in A7r5 vascular myocytes. Eur. J. Pharmacol. 2007, 577:91-99.
65. Shen M., Zhao L., Wu R.X., Yue S.Q., Pei J.M. The vasorelaxing effect of resveratrol on abdominal aorta from rats and its underlying mechanisms. Vascul. Pharmacol. 2013, 58:64-70.
66. Ma H.J., Cao Y.K., Liu Y.X., Wang R., Wu Y.M. Microinjection of resveratrol into rostral ventrolateral medulla decreases sympathetic vasomotor tone through nitric oxide and intracellular Ca2+ in anesthetized male rats. Acta Pharmacol. Sin. 2008, 29:906-912.
67. Cheng P.W., Ho W.Y., Su Y.T., Lu P.J., Chen B.Z., Cheng W.H., Lu W.H., Sun G.C., Yeh T.C., Hsiao M., Tseng C.J. Resveratrol decreases fructose-induced oxidative stress, mediated by NADPH oxidase via an AMPK-dependent mechanism. Br. J. Pharmacol. 2014, 171:2739-2750.
68. Chicoine L.G., Stewart J.A., Lucchesi P.A. Is resveratrol the magic bullet for pulmonary hypertension?. Hypertension 2009, 54:473-474.
69. Yang D.L., Zhang H.G., Xu Y.L., Gao Y.H., Yang X.J., Hao X.Q., Li X.H. Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats. Clin. Exp. Pharmacol. Physiol. 2010, 37:150-155.
70. Csiszar A., Labinskyy N., Olson S., Pinto J.T., Gupte S., Wu J.M., Hu F., Ballabh P., Podlutsky A., Losonczy G., de Cabo R., Mathew R., Wolin M.S., Ungvari Z. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009, 54:668-675.
71. Paffett M.L., Hesterman J., Candelaria G., Lucas S., Anderson T., Irwin D., Hoppin J., Norenberg J., Campen M.J. Longitudinal in vivo SPECT/CT imaging reveals morphological changes and cardiopulmonary apoptosis in a rodent model of pulmonary arterial hypertension. PLoS One 2012, 7:e40910.
72. Paffett M.L., Lucas S.N., Campen M.J. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle. Vascul. Pharmacol. 2012, 56:64-73.
73. Chun C., Yang W., Xueding C., Qi Z., Xiaoying H., Honglei X., Fangyou Y., Chan C., Yuanyuan L., Weixi Z., Dan Y., Zhoucang Z., Lehe Y., Cheng D., Liangxing W. Resveratrol downregulates acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 mitogen-activated protein kinase and monocyte chemoattractant protein-1 signaling in rats. Life Sci. 2012, 90:721-727.
74. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012, 32:537-541.
75. Movahed A., Nabipour I., Lieben Louis X., Thandapilly S.J., Yu L., Kalantarhormozi M., Rekabpour S.J., Netticadan T. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid. Based Complement Alternat. Med. 2013, 2013:851267.
76. Timmers S., Konings E., Bilet L., Houtkooper R.H., van de Weijer T., Goossens G.H., Hoeks J., van der Krieken S., Ryu D., Kersten S., Moonen-Kornips E., Hesselink M.K., Kunz I., Schrauwen-Hinderling V.B., Blaak E.E., Auwerx J., Schrauwen P. Calorie restriction-like effects of 30days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14:612-622.
77. Tome-Carneiro J., Gonzalvez M., Larrosa M., Yanez-Gascon M.J., Garcia-Almagro F.J., Ruiz-Ros J.A., Garcia-Conesa M.T., Tomas-Barberan F.A., Espin J.C. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 2012, 110:356-363.
78. Yoshino J., Conte C., Fontana L., Mittendorfer B., Imai S., Schechtman K.B., Gu C., Kunz I., Rossi Fanelli F., Patterson B.W., Klein S. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012, 16:658-664.
79. Fujitaka K., Otani H., Jo F., Jo H., Nomura E., Iwasaki M., Nishikawa M., Iwasaka T., Das D.K. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr. Res. 2011, 31:842-847.
80. Liu Y., Ma W., Zhang P., He S., Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin. Nutr. 2014, 10.1016/j.clnu.2014.03.009.
81. Soare A., Weiss E.P., Holloszy J.O., Fontana L. Multiple dietary supplements do not affect metabolic and cardio-vascular health. Aging (Albany NY) 2014, 6:149-157.
82. Wong R.H., Berry N.M., Coates A.M., Buckley J.D., Bryan J., Kunz I., Howe P.R. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J. Hypertens. 2013, 31:1819-1827.
83. Bentzon J.F., Otsuka F., Virmani R., Falk E. Mechanisms of plaque formation and rupture. Circ. Res. 2014, 114:1852-1866.
84. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., Watson A.D., Lusis A.J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995, 91:2488-2496.
85. Chu L.M., Lassaletta A.D., Robich M.P., Sellke F.W. Resveratrol in the prevention and treatment of coronary artery disease. Curr. Atheroscler. Rep. 2011, 13:439-446.
86. Tonkin A., Byrnes A. Treatment of dyslipidemia. F1000Prime Rep 2014, 6:17.
87. Ahn J., Cho I., Kim S., Kwon D., Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J. Hepatol. 2008, 49:1019-1028.
88. Cho I.J., Ahn J.Y., Kim S., Choi M.S., Ha T.Y. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem. Biophys. Res. Commun. 2008, 367:190-194.
89. Do G.M., Kwon E.Y., Kim H.J., Jeon S.M., Ha T.Y., Park T., Choi M.S. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem. Biophys. Res. Commun. 2008, 374:55-59.
90. Penumathsa S.V., Thirunavukkarasu M., Koneru S., Juhasz B., Zhan L., Pant R., Menon V.P., Otani H., Maulik N. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J. Mol. Cell. Cardiol. 2007, 42:508-516.
91. Gocmen A.Y., Burgucu D., Gumuslu S. Effect of resveratrol on platelet activation in hypercholesterolemic rats: CD40-CD40L system as a potential target. Appl. Physiol. Nutr. Metab. 2011, 36:323-330.
92. Chen Q., Wang E., Ma L., Zhai P. Dietary resveratrol increases the expression of hepatic 7alpha-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice. Lipids Health Dis. 2012, 11:56.
93. Yashiro T., Nanmoku M., Shimizu M., Inoue J., Sato R. Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element-binding proteins. Atherosclerosis 2012, 220:369-374.
94. Matos R.S., Baroncini L.A., Precoma L.B., Winter G., Lambach P.H., Caron E.Y., Kaiber F., Precoma D.B. Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arq. Bras. Cardiol. 2012, 98:136-142.
95. Wang Z., Zou J., Cao K., Hsieh T.C., Huang Y., Wu J.M. Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int. J. Mol. Med. 2005, 16:533-540.
96. Rocha K.K., Souza G.A., Ebaid G.X., Seiva F.R., Cataneo A.C., Novelli E.L. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem. Toxicol. 2009, 47:1362-1367.
97. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
98. Berrougui H., Grenier G., Loued S., Drouin G., Khalil A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 2009, 207:420-427.
99. Li Y., Cao Z., Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol. Res. 2006, 53:6-15.
100. Ungvari Z., Bagi Z., Feher A., Recchia F.A., Sonntag W.E., Pearson K., de Cabo R., Csiszar A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H18-H24.
101. Voloshyna I., Hai O., Littlefield M.J., Carsons S., Reiss A.B. Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARgamma and adenosine. Eur. J. Pharmacol. 2013, 698:299-309.
102. Ramprasath V.R., Jones P.J. Anti-atherogenic effects of resveratrol. Eur. J. Clin. Nutr. 2010, 64:660-668.
103. Wakabayashi I., Takeda Y. Inhibitory effects of resveratrol on MCP-1, IL-6, and IL-8 production in human coronary artery smooth muscle cells. Naunyn Schmiedebergs Arch. Pharmacol. 2013, 386:835-839.
104. Zhong M., Cheng G.F., Wang W.J., Guo Y., Zhu X.Y., Zhang J.T. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 1999, 6:79-84.
105. Song R., Li W.Q., Dou J.L., Li L., Hu Y.J., Guo J.Z., Lu D., Zhang G., Sun L. Resveratrol reduces inflammatory cytokines via inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signal pathway in a rabbit atherosclerosis model. Zhonghua Xin Xue Guan Bing Za Zhi 2013, 41:866-869.
106. Deng Y.H., Alex D., Huang H.Q., Wang N., Yu N., Wang Y.T., Leung G.P., Lee S.M. Inhibition of TNF-alpha-mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3,5,4'-trimethoxystilbene. Phytother. Res. 2011, 25:451-457.
107. Ferrero M.E., Bertelli A.E., Fulgenzi A., Pellegatta F., Corsi M.M., Bonfrate M., Ferrara F., De Caterina R., Giovannini L., Bertelli A. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am. J. Clin. Nutr. 1998, 68:1208-1214.
108. Kim S.W., Kim C.E., Kim M.H. Flavonoids inhibit high glucose-induced up-regulation of ICAM-1 via the p38 MAPK pathway in human vein endothelial cells. Biochem. Biophys. Res. Commun. 2011, 415:602-607.
109. Scoditti E., Calabriso N., Massaro M., Pellegrino M., Storelli C., Martines G., De Caterina R., Carluccio M.A. Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch. Biochem. Biophys. 2012, 527:81-89.
110. Annabi B., Lord-Dufour S., Vezina A., Beliveau R. Resveratrol targeting of carcinogen-induced brain endothelial cell inflammation biomarkers MMP-9 and COX-2 is Sirt1-independent. Drug Target Insights 2012, 6:1-11.
111. Park D.W., Baek K., Kim J.R., Lee J.J., Ryu S.H., Chin B.R., Baek S.H. Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp. Mol. Med. 2009, 41:171-179.
112. Chen F., Qian L.H., Deng B., Liu Z.M., Zhao Y., Le Y.Y. Resveratrol protects vascular endothelial cells from high glucose-induced apoptosis through inhibition of NADPH oxidase activation-driven oxidative stress. CNS Neurosci. Ther. 2013, 19:675-681.
113. Chow S.E., Hshu Y.C., Wang J.S., Chen J.K. Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J. Appl. Physiol. 1985, 102(2007):1520-1527.
114. Buttari B., Profumo E., Segoni L., D'Arcangelo D., Rossi S., Facchiano F., Saso L., Businaro R., Iuliano L., Rigano R. Resveratrol counteracts inflammation in human M1 and M2 macrophages upon challenge with 7-oxo-cholesterol: potential therapeutic implications in atherosclerosis. Oxid. Med. Cell. Longev. 2014, 2014:257543.
115. Csiszar A., Sosnowska D., Wang M., Lakatta E.G., Sonntag W.E., Ungvari Z. Age-associated proinflammatory secretory phenotype in vascular smooth muscle cells from the non-human primate Macaca mulatta: reversal by resveratrol treatment. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67:811-820.
116. Wang A., Liu M., Liu X., Dong L.Q., Glickman R.D., Slaga T.J., Zhou Z., Liu F. Up-regulation of adiponectin by resveratrol: the essential roles of the Akt/FOXO1 and AMP-activated protein kinase signaling pathways and DsbA-L. J. Biol. Chem. 2011, 286:60-66.
117. Rojas E., Rodriguez-Molina D., Bolli P., Israili Z.H., Faria J., Fidilio E., Bermudez V., Velasco M. The role of adiponectin in endothelial dysfunction and hypertension. Curr. Hypertens. Rep. 2014, 16:463.
118. Venkatesan B., Valente A.J., Reddy V.S., Siwik D.A., Chandrasekar B. Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H874-H886.
119. Lin Y.C., Chen L.H., Varadharajan T., Tsai M.J., Chia Y.C., Yuan T.C., Sung P.J., Weng C.F. Resveratrol inhibits glucose-induced migration of vascular smooth muscle cells mediated by focal adhesion kinase. Mol. Nutr. Food Res. 2014, 58:1389-1401.
120. Kumerz M., Heiss E.H., Schachner D., Atanasov A.G., Dirsch V.M. Resveratrol inhibits migration and Rac1 activation in EGF- but not PDGF-activated vascular smooth muscle cells. Mol. Nutr. Food Res. 2011, 55:1230-1236.
121. Brito P.M., Devillard R., Negre-Salvayre A., Almeida L.M., Dinis T.C., Salvayre R., Auge N. Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells. Atherosclerosis 2009, 205:126-134.
122. Shi Y., Hou X., Zhang X., Wang Y., Chen Y., Zou J. Inhibition of oxidized-phospholipid-induced vascular smooth muscle cell proliferation by resveratrol is associated with reducing Cx43 phosphorylation. J. Agric. Food Chem. 2013, 61:10534-10541.
123. El-Mowafy A.M., Alkhalaf M., El-Kashef H.A. Resveratrol reverses hydrogen peroxide-induced proliferative effects in human coronary smooth muscle cells: a novel signaling mechanism. Arch. Med. Res. 2008, 39:155-161.
124. Guo R., Li W., Liu B., Li S., Zhang B., Xu Y. Resveratrol protects vascular smooth muscle cells against high glucose-induced oxidative stress and cell proliferation in vitro. Med. Sci. Monit. Basic Res. 2014, 20:82-92.
125. Breen D.M., Dolinsky V.W., Zhang H., Ghanim H., Guo J., Mroziewicz M., Tsiani E.L., Bendeck M.P., Dandona P., Dyck J.R., Heximer S.P., Giacca A. Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Atherosclerosis 2012, 222:375-381.
126. Thompson A.M., Martin K.A., Rzucidlo E.M. Resveratrol induces vascular smooth muscle cell differentiation through stimulation of SirT1 and AMPK. PLoS One 2014, 9:e85495.
127. Zheng J.P., Ju D., Jiang H., Shen J., Yang M., Li L. Resveratrol induces p53 and suppresses myocardin-mediated vascular smooth muscle cell differentiation. Toxicol. Lett. 2010, 199:115-122.
128. Olas B., Wachowicz B., Saluk-Juszczak J., Zielinski T. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb. Res. 2002, 107:141-145.
129. Shen M.Y., Hsiao G., Liu C.L., Fong T.H., Lin K.H., Chou D.S., Sheu J.R. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br. J. Haematol. 2007, 139:475-485.
130. Yang Y., Wang X., Zhang L., An H., Zao Z. Inhibitory effects of resveratrol on platelet activation induced by thromboxane a(2) receptor agonist in human platelets. Am. J. Chin. Med. 2011, 39:145-159.
131. Yang Y.M., Chen J.Z., Wang X.X., Wang S.J., Hu H., Wang H.Q. Resveratrol attenuates thromboxane A2 receptor agonist-induced platelet activation by reducing phospholipase C activity. Eur. J. Pharmacol. 2008, 583:148-155.
132. Lin K.H., Hsiao G., Shih C.M., Chou D.S., Sheu J.R. Mechanisms of resveratrol-induced platelet apoptosis. Cardiovasc. Res. 2009, 83:575-585.
133. de Lange D.W., Verhoef S., Gorter G., Kraaijenhagen R.J., van de Wiel A., Akkerman J.W. Polyphenolic grape extract inhibits platelet activation through PECAM-1: an explanation for the French paradox. Alcohol. Clin. Exp. Res. 2007, 31:1308-1314.
134. Stef G., Csiszar A., Lerea K., Ungvari Z., Veress G. Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J. Cardiovasc. Pharmacol. 2006, 48:1-5.
135. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K., Topol E.J. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 2001, 88:230-235.
136. Bo S., Ciccone G., Castiglione A., Gambino R., De Michieli F., Villois P., Durazzo M., Cavallo-Perin P., Cassader M. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr. Med. Chem. 2013, 20:1323-1331.
137. Tome-Carneiro J., Gonzalvez M., Larrosa M., Garcia-Almagro F.J., Aviles-Plaza F., Parra S., Yanez-Gascon M.J., Ruiz-Ros J.A., Garcia-Conesa M.T., Tomas-Barberan F.A., Espin J.C. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 2012, 56:810-821.
138. Dash S., Xiao C., Morgantini C., Szeto L., Lewis G.F. High-dose resveratrol treatment for 2weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2895-2901.
139. Poulsen M.M., Vestergaard P.F., Clasen B.F., Radko Y., Christensen L.P., Stodkilde-Jorgensen H., Moller N., Jessen N., Pedersen S.B., Jorgensen J.O. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62:1186-1195.
140. Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr. Rev. 2013, 71:822-835.
141. Ghanim H., Sia C.L., Abuaysheh S., Korzeniewski K., Patnaik P., Marumganti A., Chaudhuri A., Dandona P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J. Clin. Endocrinol. Metab. 2010, 95:E1-E8.
142. Clark D., Tuor U.I., Thompson R., Institoris A., Kulynych A., Zhang X., Kinniburgh D.W., Bari F., Busija D.W., Barber P.A. Protection against recurrent stroke with resveratrol: endothelial protection. PLoS One 2012, 7:e47792.
143. Huang S.S., Tsai M.C., Chih C.L., Hung L.M., Tsai S.K. Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia. Life Sci. 2001, 69:1057-1065.
144. Simao F., Pagnussat A.S., Seo J.H., Navaratna D., Leung W., Lok J., Guo S., Waeber C., Salbego C.G., Lo E.H. Pro-angiogenic effects of resveratrol in brain endothelial cells: nitric oxide-mediated regulation of vascular endothelial growth factor and metalloproteinases. J. Cereb. Blood Flow Metab. 2012, 32:884-895.
145. Arrick D.M., Sun H., Patel K.P., Mayhan W.G. Chronic resveratrol treatment restores vascular responsiveness of cerebral arterioles in type 1 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H696-H703.
146. Ren J., Fan C., Chen N., Huang J., Yang Q. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem. Res. 2011, 36:2352-2362.
147. Ishrat T., Mohamed I.N., Pillai B., Soliman S., Fouda A.Y., Ergul A., El-Remessy A.B., Fagan S.C. Thioredoxin-interacting protein: a novel target for neuroprotection in experimental thromboembolic stroke in mice. Mol. Neurobiol. 2014, 10.1007/s12035-014-8766-x.
148. Wang L.M., Wang Y.J., Cui M., Luo W.J., Wang X.J., Barber P.A., Chen Z.Y. A dietary polyphenol resveratrol acts to provide neuroprotection in recurrent stroke models by regulating AMPK and SIRT1 signaling, thereby reducing energy requirements during ischemia. Eur. J. Neurosci. 2013, 37:1669-1681.
149. Lin Y., Chen F., Zhang J., Wang T., Wei X., Wu J., Feng Y., Dai Z., Wu Q. Neuroprotective effect of resveratrol on ischemia/reperfusion injury in rats through TRPC6/CREB pathways. J. Mol. Neurosci. 2013, 50:504-513.
150. Li Z., Pang L., Fang F., Zhang G., Zhang J., Xie M., Wang L. Resveratrol attenuates brain damage in a rat model of focal cerebral ischemia via up-regulation of hippocampal Bcl-2. Brain Res. 2012, 1450:116-124.
151. Singh N., Agrawal M., Dore S. Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models. ACS Chem. Neurosci. 2013, 4:1151-1162.
152. Wightman E.L., Reay J.L., Haskell C.F., Williamson G., Dew T.P., Kennedy D.O. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation. Br. J. Nutr. 2014, 112:203-213.
153. Kennedy D.O., Wightman E.L., Reay J.L., Lietz G., Okello E.J., Wilde A., Haskell C.F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr. 2010, 91:1590-1597.
154. Hausenloy D.J., Yellon D.M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 2013, 123:92-100.
155. Hascalik S., Celik O., Turkoz Y., Hascalik M., Cigremis Y., Mizrak B., Yologlu S. Resveratrol, a red wine constituent polyphenol, protects from ischemia-reperfusion damage of the ovaries. Gynecol. Obstet. Invest. 2004, 57:218-223.
156. Uguralp S., Mizrak B., Bay Karabulut A. Resveratrol reduces ischemia reperfusion injury after experimental testicular torsion. Eur. J. Pediatr. Surg. 2005, 15:114-119.
157. Raj P., Louis X.L., Thandapilly S.J., Movahed A., Zieroth S., Netticadan T. Potential of resveratrol in the treatment of heart failure. Life Sci. 2014, 95:63-71.
158. Chen Y.R., Yi F.F., Li X.Y., Wang C.Y., Chen L., Yang X.C., Su P.X., Cai J. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc. Drugs Ther. 2008, 22:479-485.
159. Fukuda S., Kaga S., Zhan L., Bagchi D., Das D.K., Bertelli A., Maulik N. Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem. Biophys. 2006, 44:43-49.
160. Hung L.M., Su M.J., Chen J.K. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic. Biol. Med. 2004, 36:774-781.
161. Kaga S., Zhan L., Matsumoto M., Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell. Cardiol. 2005, 39:813-822.
162. Robich M.P., Osipov R.M., Nezafat R., Feng J., Clements R.T., Bianchi C., Boodhwani M., Coady M.A., Laham R.J., Sellke F.W. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 2010, 122:S142-S149.
163. Shen M., Jia G.L., Wang Y.M., Ma H. Cardioprotective effect of resveratrol pretreatment on myocardial ischemia-reperfusion induced injury in rats. Vascul. Pharmacol. 2006, 45:122-126.
164. Shalwala M., Zhu S.G., Das A., Salloum F.N., Xi L., Kukreja R.C. Sirtuin 1 (SIRT1) activation mediates sildenafil induced delayed cardioprotection against ischemia-reperfusion injury in mice. PLoS One 2014, 9:e86977.
165. Burstein B., Maguy A., Clement R., Gosselin H., Poulin F., Ethier N., Tardif J.C., Hebert T.E., Calderone A., Nattel S. Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. J. Pharmacol. Exp. Ther. 2007, 323:916-923.
166. Gurusamy N., Lekli I., Mukherjee S., Ray D., Ahsan M.K., Gherghiceanu M., Popescu L.M., Das D.K. Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc. Res. 2010, 86:103-112.
167. Lin J.F., Lin S.M., Chih C.L., Nien M.W., Su H.H., Hu B.R., Huang S.S., Tsai S.K. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci. 2008, 83:313-317.
168. Xuan W., Wu B., Chen C., Chen B., Zhang W., Xu D., Bin J., Liao Y. Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine*. Crit. Care Med. 2012, 40:3026-3033.
169. Gu X.S., Wang Z.B., Ye Z., Lei J.P., Li L., Su D.F., Zheng X. Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure. Genet. Mol. Res. 2014, 13:323-335.
170. Mukoyama M., Nakao K., Hosoda K., Suga S., Saito Y., Ogawa Y., Shirakami G., Jougasaki M., Obata K., Yasue H., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest. 1991, 87:1402-1412.
171. Kanamori H., Takemura G., Goto K., Tsujimoto A., Ogino A., Takeyama T., Kawaguchi T., Watanabe T., Morishita K., Kawasaki M., Mikami A., Fujiwara T., Fujiwara H., Seishima M., Minatoguchi S. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am. J. Pathol. 2013, 182:701-713.
172. Ikizler M., Ovali C., Dernek S., Erkasap N., Sevin B., Kaygisiz Z., Kural T. Protective effects of resveratrol in ischemia-reperfusion injury of skeletal muscle: a clinically relevant animal model for lower extremity ischemia. Chin. J. Physiol. 2006, 49:204-209.
173. Elmali N., Esenkaya I., Karadag N., Tas F. Effects of resveratrol on skeletal muscle in ischemia-reperfusion injury. Ulus. Travma Acil Cerrahi Derg. 2007, 13:274-280.
174. Budak B., Seren M., Turan N.N., Sakaogullari Z., Ulus A.T. The protective effects of resveratrol and l-NAME on visceral organs following aortic clamping. Ann. Vasc. Surg. 2009, 23:675-685.
175. Sener G., Tugtepe H., Yuksel M., Cetinel S., Gedik N., Yegen B.C. Resveratrol improves ischemia/reperfusion-induced oxidative renal injury in rats. Arch. Med. Res. 2006, 37:822-829.
176. Forstermann U., Sessa W.C. Nitric oxide synthases: regulation and function. Eur. Heart J. 2012, 33:829-837. (837a-837d).
177. Jones S.P., Girod W.G., Palazzo A.J., Granger D.N., Grisham M.B., Jourd'Heuil D., Huang P.L., Lefer D.J. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am. J. Physiol. 1999, 276:H1567-H1573.
178. Sharp B.R., Jones S.P., Rimmer D.M., Lefer D.J. Differential response to myocardial reperfusion injury in eNOS-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:H2422-H2426.
179. Elrod J.W., Greer J.J., Bryan N.S., Langston W., Szot J.F., Gebregzlabher H., Janssens S., Feelisch M., Lefer D.J. Cardiomyocyte-specific overexpression of NO synthase-3 protects against myocardial ischemia-reperfusion injury. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1517-1523.
180. Jones S.P., Greer J.J., Kakkar A.K., Ware P.D., Turnage R.H., Hicks M., van Haperen R., de Crom R., Kawashima S., Yokoyama M., Lefer D.J. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H276-H282.
181. Bradamante S., Barenghi L., Piccinini F., Bertelli A.A., De Jonge R., Beemster P., De Jong J.W. Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism. Eur. J. Pharmacol. 2003, 465:115-123.
182. Cooke J.P., Losordo D.W. Nitric oxide and angiogenesis. Circulation 2002, 105:2133-2135.
183. Nagoshi T., Matsui T., Aoyama T., Leri A., Anversa P., Li L., Ogawa W., del Monte F., Gwathmey J.K., Grazette L., Hemmings B.A., Kass D.A., Champion H.C., Rosenzweig A. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J. Clin. Invest. 2005, 115:2128-2138.
184. Chen P.L., Easton A.S. Anti-angiogenic effects of resveratrol on cerebral angiogenesis. Curr. Neurovasc. Res. 2011, 8:14-24.
185. Robich M.P., Chu L.M., Chaudray M., Nezafat R., Han Y., Clements R.T., Laham R.J., Manning W.J., Coady M.A., Sellke F.W. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery 2010, 148:453-462.
186. Ganapathy S., Chen Q., Singh K.P., Shankar S., Srivastava R.K. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS One 2010, 5:e15627.
187. Tseng S.H., Lin S.M., Chen J.C., Su Y.H., Huang H.Y., Chen C.K., Lin P.Y., Chen Y. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin. Cancer Res. 2004, 10:2190-2202.
188. Dhalla N.S., Temsah R.M., Netticadan T. Role of oxidative stress in cardiovascular diseases. J. Hypertens. 2000, 18:655-673.
189. Shen M., Wu R.X., Zhao L., Li J., Guo H.T., Fan R., Cui Y., Wang Y.M., Yue S.Q., Pei J.M. Resveratrol attenuates ischemia/reperfusion injury in neonatal cardiomyocytes and its underlying mechanism. PLoS One 2012, 7:e51223.
190. Hwang J.T., Kwon D.Y., Park O.J., Kim M.S. Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr. 2008, 2:323-326.
191. Sabe A.A., Sadek A.A., Elmadhun N.Y., Dalal R.S., Robich M.P., Bianchi C., Sellke F.W. Investigating the effects of resveratrol on chronically ischemic myocardium in a swine model of metabolic syndrome: a proteomics analysis. J. Med. Food 2014, 10.1089/jmf.2014.0036.
192. Kanamori H., Takemura G., Goto K., Maruyama R., Tsujimoto A., Ogino A., Takeyama T., Kawaguchi T., Watanabe T., Fujiwara T., Fujiwara H., Seishima M., Minatoguchi S. The role of autophagy emerging in postinfarction cardiac remodelling. Cardiovasc. Res. 2011, 91:330-339.
193. Wang B., Yang Q., Sun Y.Y., Xing Y.F., Wang Y.B., Lu X.T., Bai W.W., Liu X.Q., Zhao Y.X. Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice. J. Cell. Mol. Med. 2014, 18(8):1599-1611.
194. Militaru C., Donoiu I., Craciun A., Scorei I.D., Bulearca A.M., Scorei R.I. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition 2013, 29:178-183.
195. Scorei R.I., Rotaru P. Calcium fructoborate-potential anti-inflammatory agent. Biol. Trace Elem. Res. 2011, 143:1223-1238.
196. Tome-Carneiro J., Gonzalvez M., Larrosa M., Yanez-Gascon M.J., Garcia-Almagro F.J., Ruiz-Ros J.A., Tomas-Barberan F.A., Garcia-Conesa M.T., Espin J.C. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 2013, 27:37-48.
197. Barseghian A., Gawande D., Bajaj M. Adiponectin and vulnerable atherosclerotic plaques. J. Am. Coll. Cardiol. 2011, 57:761-770.
198. Maruyoshi H., Kojima S., Funahashi T., Miyamoto S., Hokamaki J., Soejima H., Sakamoto T., Kawano H., Yoshimura M., Kitagawa A., Matsuzawa Y., Ogawa H. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb. Haemost. 2004, 91:1026-1030.
199. Magyar K., Halmosi R., Palfi A., Feher G., Czopf L., Fulop A., Battyany I., Sumegi B., Toth K., Szabados E. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 2012, 50:179-187.
200. McMurray J.J., Pfeffer M.A. Heart failure. Lancet 2005, 365:1877-1889.
201. Huynh K., Bernardo B.C., McMullen J.R., Ritchie R.H. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol. Ther. 2014, 142:375-415.
202. Hong R.A., Iimura T., Sumida K.N., Eager R.M. Cardio-oncology/onco-cardiology. Clin. Cardiol. 2010, 33:733-737.
203. Ferroni P., Della-Morte D., Palmirotta R., McClendon M., Testa G., Abete P., Rengo F., Rundek T., Guadagni F., Roselli M. Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention. Rejuvenation Res. 2011, 14:293-308.
204. Kaye D.M., Krum H. Drug discovery for heart failure: a new era or the end of the pipeline?. Nat. Rev. Drug Discov. 2007, 6:127-139.
205. McKinsey T.A., Kass D.A. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev. Drug Discov. 2007, 6:617-635.
206. Mudd J.O., Kass D.A. Tackling heart failure in the twenty-first century. Nature 2008, 451:919-928.
207. Houser S.R., Margulies K.B., Murphy A.M., Spinale F.G., Francis G.S., Prabhu S.D., Rockman H.A., Kass D.A., Molkentin J.D., Sussman M.A., Koch W.J., C.o.C.C.American Heart Association Council on Basic Cardiovascular Sciences, G.Council on Functional, B.Translational Animal models of heart failure: a scientific statement from the American Heart Association. Circ. Res. 2012, 111:131-150.
208. Juric D., Wojciechowski P., Das D.K., Netticadan T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H2138-H2143.
209. Gupta P.K., DiPette D.J., Supowit S.C. Protective effect of resveratrol against pressure overload-induced heart failure. Food Sci. Nutr. 2014, 2:218-229.
210. Wojciechowski P., Juric D., Louis X.L., Thandapilly S.J., Yu L., Taylor C., Netticadan T. Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. J. Nutr. 2010, 140:962-968.
211. Yoshida Y., Shioi T., Izumi T. Resveratrol ameliorates experimental autoimmune myocarditis. Circ. J. 2007, 71:397-404.
212. Tanno M., Kuno A., Yano T., Miura T., Hisahara S., Ishikawa S., Shimamoto K., Horio Y. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J. Biol. Chem. 2010, 285:8375-8382.
213. Devereux R.B., Wachtell K., Gerdts E., Boman K., Nieminen M.S., Papademetriou V., Rokkedal J., Harris K., Aurup P., Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004, 292:2350-2356.
214. Thandapilly S.J., LeMaistre J.L., Louis X.L., Anderson C.M., Netticadan T., Anderson H.D. Vascular and cardiac effects of grape powder in the spontaneously hypertensive rat. Am. J. Hypertens 2012, 10:1070-1076.
215. Biala A., Tauriainen E., Siltanen A., Shi J., Merasto S., Louhelainen M., Martonen E., Finckenberg P., Muller D.N., Mervaala E. Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Blood Press. 2010, 19:196-205.
216. Chan A.Y., Dolinsky V.W., Soltys C.L., Viollet B., Baksh S., Light P.E., Dyck J.R. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J. Biol. Chem. 2008, 283:24194-24201.
217. Rimbaud S., Ruiz M., Piquereau J., Mateo P., Fortin D., Veksler V., Garnier A., Ventura-Clapier R. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS One 2011, 6:e26391.
218. Seddon M., Looi Y.H., Shah A.M. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007, 93:903-907.
219. Tu V.C., Bahl J.J., Chen Q.M. Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. J. Pharmacol. Exp. Ther. 2002, 300:1101-1110.
220. Kempf T., Wollert K.C. Nitric oxide and the enigma of cardiac hypertrophy. Bioessays 2004, 26:608-615.
221. Hannan R.D., Jenkins A., Jenkins A.K., Brandenburger Y. Cardiac hypertrophy: a matter of translation. Clin. Exp. Pharmacol. Physiol. 2003, 30:517-527.
222. Hedhli N., Pelat M., Depre C. Protein turnover in cardiac cell growth and survival. Cardiovasc. Res. 2005, 68:186-196.
223. Zordoky B.N., El-Kadi A.O. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and beta-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism. Toxicol. In Vitro 2010, 24:863-871.
224. Franke T.F., Kaplan D.R., Cantley L.C. PI3K: downstream AKTion blocks apoptosis. Cell 1997, 88:435-437.
225. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
226. Thandapilly S.J., Louis X.L., Yang T., Stringer D.M., Yu L., Zhang S., Wigle J., Kardami E., Zahradka P., Taylor C., Anderson H.D., Netticadan T. Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway. Eur. J. Pharmacol. 2011, 668:217-224.
227. Dolinsky V.W., Dyck J.R. Experimental studies of the molecular pathways regulated by exercise and resveratrol in heart, skeletal muscle and the vasculature. Molecules 2014, 19:14919-14947.
228. Dolinsky V.W., Dyck J.R. Role of AMP-activated protein kinase in healthy and diseased hearts. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2557-H2569.
229. Sundaresan N.R., Pillai V.B., Gupta M.P. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J. Mol. Cell. Cardiol. 2011, 51:614-618.
230. Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P., Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci. Signal. 2011, 4:ra46.
231. Alcendor R.R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., Tian B., Wagner T., Vatner S.F., Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 2007, 100:1512-1521.
232. Ikeda Y. Modification of sarco-endoplasmic reticulum Ca(2+)-ATPase in the failing cardiomyocyte. Clin. Calcium 2013, 23:535-542.
233. Sulaiman M., Matta M.J., Sunderesan N.R., Gupta M.P., Periasamy M., Gupta M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H833-H843.
234. Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A.L., Kim M.K., Beaven M.A., Burgin A.B., Manganiello V., Chung J.H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148:421-433.
235. Deng J., Liu W., Wang Y., Dong M., Zheng M., Liu J. Polydatin modulates Ca(2+) handling, excitation-contraction coupling and beta-adrenergic signaling in rat ventricular myocytes. J. Mol. Cell. Cardiol. 2012, 53:646-656.
236. Wilkins B.J., Molkentin J.D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun. 2004, 322:1178-1191.
237. Li H.L., Yin R., Chen D., Liu D., Wang D., Yang Q., Dong Y.G. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J. Cell. Biochem. 2007, 100:1086-1099.
238. Zhou L., Deng W., Fang P., He D., Zhang W., Liu K., Hu R. Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review. Curr. Diabetes Rev. 2009, 5:171-184.
239. Bertoni A.G., Tsai A., Kasper E.K., Brancati F.L. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 2003, 26:2791-2795.
240. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 1972, 30:595-602.
241. Varga Z.V., Giricz Z., Liaudet L., Hasko G., Ferdinandy P., Pacher P. Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim. Biophys. Acta 2015, 1852:232-242.
242. Carolo dos Santos K., Pereira Braga C., Octavio Barbanera P., Seiva F.R., Fernandes Junior A., Fernandes A.A. Cardiac energy metabolism and oxidative stress biomarkers in diabetic rat treated with resveratrol. PLoS One 2014, 9:e102775.
243. Su H.C., Hung L.M., Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E1339-E1346.
244. Bagul P.K., Middela H., Matapally S., Padiya R., Bastia T., Madhusudana K., Reddy B.R., Chakravarty S., Banerjee S.K. Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol. Res. 2012, 66:260-268.
245. Turan B., Tuncay E., Vassort G. Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. J. Bioenerg. Biomembr. 2012, 44:281-296.
246. Thirunavukkarasu M., Penumathsa S.V., Koneru S., Juhasz B., Zhan L., Otani H., Bagchi D., Das D.K., Maulik N. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic. Biol. Med. 2007, 43:720-729.
247. Penumathsa S.V., Thirunavukkarasu M., Zhan L., Maulik G., Menon V.P., Bagchi D., Maulik N. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J. Cell. Mol. Med. 2008, 12:2350-2361.
248. Bertrand L., Ginion A., Beauloye C., Hebert A.D., Guigas B., Hue L., Vanoverschelde J.L. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H239-H250.
249. Delucchi F., Berni R., Frati C., Cavalli S., Graiani G., Sala R., Chaponnier C., Gabbiani G., Calani L., Del Rio D., Bocchi L., Lagrasta C., Quaini F., Stilli D. Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats. PLoS One 2012, 7:e39836.
250. Wang B., Yang Q., Sun Y.Y., Xing Y.F., Wang Y.B., Lu X.T., Bai W.W., Liu X.Q., Zhao Y.X. Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice. J. Cell. Mol. Med. 2014, 18:1599-1611.
251. Bresciani L., Calani L., Bocchi L., Delucchi F., Savi M., Ray S., Brighenti F., Stilli D., Del Rio D. Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats. Nutr. Metab. Cardiovasc. Dis. 2014, 24:408-415.
252. Zhang H., Morgan B., Potter B.J., Ma L., Dellsperger K.C., Ungvari Z., Zhang C. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H985-H994.
253. Zhang H., Zhang J., Ungvari Z., Zhang C. Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1164-1171.
254. Mohammadshahi M., Haidari F., Soufi F.G. Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress. Cardiol. J. 2014, 21:39-46.
255. Balteau M., Tajeddine N., de Meester C., Ginion A., Des Rosiers C., Brady N.R., Sommereyns C., Horman S., Vanoverschelde J.L., Gailly P., Hue L., Bertrand L., Beauloye C. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc. Res. 2011, 92:237-246.
256. Balteau M., Van Steenbergen A., Timmermans A.D., Dessy C., Behets-Wydemans G., Tajeddine N., Castanares-Zapatero D., Gilon P., Vanoverschelde J.L., Horman S., Hue L., Bertrand L., Beauloye C. AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2014, 307(8):H1120-H1133.
257. Beaudoin M.S., Perry C.G., Arkell A.M., Chabowski A., Simpson J.A., Wright D.C., Holloway G.P. Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats. J. Physiol. 2014, 592:2519-2533.
258. Brasnyo P., Molnar G.A., Mohas M., Marko L., Laczy B., Cseh J., Mikolas E., Szijarto I.A., Merei A., Halmai R., Meszaros L.G., Sumegi B., Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011, 106:383-389.
259. Liu K., Zhou R., Wang B., Mi M.T. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 2014, 99:1510-1519.
260. Picard F., dos Santos P., Catargi B. Diabetes, obesity and heart complications. Rev. Prat. 2013, 63:759-764.
261. Arafa M.H., Mohammad N.S., Atteia H.H., Abd-Elaziz H.R. Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J. Physiol. Biochem. 2014, 70(3):701-711.
262. Dolinsky V.W., Rogan K.J., Sung M.M., Zordoky B.N., Haykowsky M.J., Young M.E., Jones L.W., Dyck J.R. Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am. J. Physiol. Endocrinol. Metab. 2013, 305:E243-E253.
263. Tatlidede E., Sehirli O., Velioglu-Ogunc A., Cetinel S., Yegen B.C., Yarat A., Suleymanoglu S., Sener G. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic. Res. 2009, 43:195-205.
264. Wang G.Y., Wang Y.M., Zhang L.N., Li Q., Yue H., Song C.M., Feng J.K., Wang N. Effect of resveratrol on heart function of rats with adriamycin-induced heart failure. Zhongguo Zhong Yao Za Zhi 2007, 32:1563-1565.
265. Osman A.M., Al-Harthi S.E., AlArabi O.M., Elshal M.F., Ramadan W.S., Alaama M.N., Al-Kreathy H.M., Damanhouri Z.A., Osman O.H. Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin-treated animals. Cancer Cell Int. 2013, 13:52.
266. Rezk Y.A., Balulad S.S., Keller R.S., Bennett J.A. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am. J. Obstet. Gynecol. 2006, 194:e23-e26.
267. Salazar-Mendiguchia J., Gonzalez-Costello J., Roca J., Ariza-Sole A., Manito N., Cequier A. Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist. Arch. Cardiol. Mex. 2014, 84(3):218-223.
268. Cao Z., Li Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur. J. Pharmacol. 2004, 489:39-48.
269. Danz E.D., Skramsted J., Henry N., Bennett J.A., Keller R.S. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic. Biol. Med. 2009, 46:1589-1597.
270. Wang J., He D., Zhang Q., Han Y., Jin S., Qi F. Resveratrol protects against cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biother. Radiopharm. 2009, 24:675-680.
271. Gu J., Song Z.P., Gui D.M., Hu W., Chen Y.G., Zhang D.D. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by heme oxygenase-1 induction. Cardiovasc. Toxicol. 2012, 12:341-349.
272. Wang S., Song P., Zou M.H. Inhibition of AMP-activated protein kinase alpha (AMPKalpha) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. J. Biol. Chem. 2012, 287:8001-8012.
273. Xu X., Chen K., Kobayashi S., Timm D., Liang Q. Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J. Pharmacol. Exp. Ther. 2012, 341:183-195.
274. Zhang C., Feng Y., Qu S., Wei X., Zhu H., Luo Q., Liu M., Chen G., Xiao X. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc. Res. 2011, 90:538-545.
275. Sterba M., Popelova O., Vavrova A., Jirkovsky E., Kovarikova P., Gersl V., Simunek T. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid. Redox Signal. 2013, 18:899-929.
276. Zhang W., Guo C., Gao R., Ge M., Zhu Y., Zhang Z. The protective role of resveratrol against arsenic trioxide-induced cardiotoxicity. Evid. Based Complement Alternat. Med. 2013, 2013:407839.
277. Zhao X.Y., Li G.Y., Liu Y., Chai L.M., Chen J.X., Zhang Y., Du Z.M., Lu Y.J., Yang B.F. Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo. Br. J. Pharmacol. 2008, 154:105-113.
278. Maayah Z.H., Ansari M.A., El Gendy M.A., Al-Arifi M.N., Korashy H.M. Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway. Arch. Toxicol. 2014, 88:725-738.
279. Al-Abd A.M., Mahmoud A.M., El-Sherbiny G.A., El-Moselhy M.A., Nofal S.M., El-Latif H.A., El-Eraky W.I., El-Shemy H.A. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif. 2011, 44:591-601.
280. Kweon S.H., Song J.H., Kim T.S. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem. Biophys. Res. Commun. 2010, 395:104-110.
281. Qian C., Ma J., Zhang P., Luo A., Wang C., Ren Z., Kong L., Zhang S., Wang X., Wu Y. Resveratrol attenuates the Na(+)-dependent intracellular Ca(2+) overload by inhibiting H(2)O(2)-induced increase in late sodium current in ventricular myocytes. PLoS One 2012, 7:e51358.
282. Baczko I., Liknes D., Yang W., Hamming K.C., Searle G., Jaeger K., Husti Z., Juhasz V., Klausz G., Pap R., Saghy L., Varro A., Dolinsky V., Wang S., Rauniyar V., Hall D., Dyck J.R., Light P.E. Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation. Br. J. Pharmacol. 2014, 171:92-106.
283. Saklani P., Skanes A. Novel anti-arrhythmic medications in the treatment of atrial fibrillation. Curr. Cardiol. Rev. 2012, 8:302-309.
284. Zhang Y., Liu Y., Wang T., Li B., Li H., Wang Z., Yang B. Resveratrol, a natural ingredient of grape skin: antiarrhythmic efficacy and ionic mechanisms. Biochem. Biophys. Res. Commun. 2006, 340:1192-1199.
285. Chen W.P., Su M.J., Hung L.M. In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant. Eur. J. Pharmacol. 2007, 554:196-204.
286. Liew R., Stagg M.A., MacLeod K.T., Collins P. The red wine polyphenol, resveratrol, exerts acute direct actions on guinea-pig ventricular myocytes. Eur. J. Pharmacol. 2005, 519:1-8.
287. Zhang L.P., Yin J.X., Liu Z., Zhang Y., Wang Q.S., Zhao J. Effect of resveratrol on L-type calcium current in rat ventricular myocytes. Acta Pharmacol. Sin. 2006, 27:179-183.
288. Li W., Wang Y.P., Gao L., Zhang P.P., Zhou Q., Xu Q.F., Zhou Z.W., Guo K., Chen R.H., Yang H.T., Li Y.G. Resveratrol protects rabbit ventricular myocytes against oxidative stress-induced arrhythmogenic activity and Ca2+ overload. Acta Pharmacol. Sin. 2013, 34:1164-1173.
289. Zhang L.P., Ma H.J., Zhao J., Wang Q.S. Effects of resveratrol on delayed afterdepolarization and triggered activity induced by ouabain in guinea pig papillary muscles. Sheng Li Xue Bao 2005, 57:361-366.
290. Anton S.D., Embry C., Marsiske M., Lu X., Doss H., Leeuwenburgh C., Manini T.M. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp. Gerontol. 2014, 57:181-187.
291. Semba R.D., Ferrucci L., Bartali B., Urpi-Sarda M., Zamora-Ros R., Sun K., Cherubini A., Bandinelli S., Andres-Lacueva C. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern. Med. 2014, 174:1077-1084.
292. Juhasz B., Mukherjee S., Das D.K. Hormetic response of resveratrol against cardioprotection. Exp. Clin. Cardiol. 2010, 15:e134-e138.
293. Gliemann L., Schmidt J.F., Olesen J., Bienso R.S., Peronard S.L., Grandjean S.U., Mortensen S.P., Nyberg M., Bangsbo J., Pilegaard H., Hellsten Y. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J. Physiol. 2013, 591:5047-5059.
294. Gliemann L., Olesen J., Bienso R.S., Schmidt J., Akerstrom T., Nyberg M., Lindqvist A., Bangsbo J., Hellsten Y. Resveratrol modulates the angiogenic response to exercise training in skeletal muscle of aged men. Am. J. Physiol. Heart Circ. Physiol. 2014, 307(8):H1111-H1119.
295. Smoliga J.M., Vang O., Baur J.A. Challenges of translating basic research into therapeutics: resveratrol as an example. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67:158-167.
296. Subramanian L., Youssef S., Bhattacharya S., Kenealey J., Polans A.S., van Ginkel P.R. Resveratrol: challenges in translation to the clinic-a critical discussion. Clin. Cancer Res. 2010, 16:5942-5948.
297. Pangeni R., Sahni J.K., Ali J., Sharma S., Baboota S. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin. Drug Deliv. 2014, 11:1285-1298.
298. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32:1377-1382.
299. Almeida L., Vaz-da-Silva M., Falcao A., Soares E., Costa R., Loureiro A.I., Fernandes-Lopes C., Rocha J.F., Nunes T., Wright L., Soares-da-Silva P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 2009, 53(Suppl. 1):S7-S15.
300. Boocock D.J., Patel K.R., Faust G.E., Normolle D.P., Marczylo T.H., Crowell J.A., Brenner D.E., Booth T.D., Gescher A., Steward W.P. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 848:182-187.
301. Azorin-Ortuno M., Yanez-Gascon M.J., Vallejo F., Pallares F.J., Larrosa M., Lucas R., Morales J.C., Tomas-Barberan F.A., Garcia-Conesa M.T., Espin J.C. Metabolites and tissue distribution of resveratrol in the pig. Mol. Nutr. Food Res. 2011, 55:1154-1168.
302. Wang D., Xu Y., Liu W. Tissue distribution and excretion of resveratrol in rat after oral administration of Polygonum cuspidatum extract (PCE). Phytomedicine 2008, 15:859-866.
303. Patel K.R., Andreadi C., Britton R.G., Horner-Glister E., Karmokar A., Sale S., Brown V.A., Brenner D.E., Singh R., Steward W.P., Gescher A.J., Brown K. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci. Transl. Med. 2013, 5:205ra133.
304. Calabrese E.J., Mattson M.P., Calabrese V. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum. Exp. Toxicol. 2010, 29:980-1015.
305. Francioso A., Mastromarino P., Restignoli R., Boffi A., d'Erme M., Mosca L. Improved stability of trans-resveratrol in aqueous solutions by carboxymethylated (1,3/1,6)-beta-d-glucan. J. Agric. Food Chem. 2014, 62:1520-1525.
306. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 2003, 65:45-79.
307. Chow H.H., Garland L.L., Hsu C.H., Vining D.R., Chew W.M., Miller J.A., Perloff M., Crowell J.A., Alberts D.S. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. (Phila.) 2010, 3:1168-1175.
308. Ras R.T., Zock P.L., Zebregs Y.E., Johnston N.R., Webb D.J., Draijer R. Effect of polyphenol-rich grape seed extract on ambulatory blood pressure in subjects with pre- and stage I hypertension. Br. J. Nutr. 2013, 110:2234-2241.
309. Tome-Carneiro J., Larrosa M., Yanez-Gascon M.J., Davalos A., Gil-Zamorano J., Gonzalvez M., Garcia-Almagro F.J., Ruiz Ros J.A., Tomas-Barberan F.A., Espin J.C., Garcia-Conesa M.T. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. 2013, 72:69-82.
310. Razavi S.M., Gholamin S., Eskandari A., Mohsenian N., Ghorbanihaghjo A., Delazar A., Rashtchizadeh N., Keshtkar-Jahromi M., Argani H. Red grape seed extract improves lipid profiles and decreases oxidized low-density lipoprotein in patients with mild hyperlipidemia. J. Med. Food 2013, 16:255-258.
311. Yubero N., Sanz-Buenhombre M., Guadarrama A., Villanueva S., Carrion J.M., Larrarte E., Moro C. LDL cholesterol-lowering effects of grape extract used as a dietary supplement on healthy volunteers. Int. J. Food Sci. Nutr. 2013, 64:400-406.
312. Kang W., Hong H.J., Guan J., Kim D.G., Yang E.J., Koh G., Park D., Han C.H., Lee Y.J., Lee D.H. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 2012, 61:424-433.
313. Hausenblas H.A., Schoulda J.A., Smoliga J.M. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus - systematic review and meta-analysis. Mol. Nutr. Food Res. 2014, 10.1002/mnfr.201400173.
314. Franco J.G., Lisboa P.C., Lima N.S., Amaral T.A., Peixoto-Silva N., Resende A.C., Oliveira E., Passos M.C., Moura E.G. Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning. J. Nutr. Biochem. 2013, 24:960-966.
315. Louis X.L., Thandapilly S.J., MohanKumar S.K., Yu L., Taylor C.G., Zahradka P., Netticadan T. Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats. J. Nutr. Biochem. 2012, 23:1163-1169.
316. Moraloglu O., Engin-Ustun Y., Tonguc E., Var T., Tapisiz O.L., Ergun H., Guvenc T., Gacar A. The effect of resveratrol on blood pressure in a rat model of preeclampsia. J. Matern. Fetal Neonatal Med. 2012, 25:845-848.
317. Subramanian M., Balasubramanian P., Garver H., Northcott C., Zhao H., Haywood J.R., Fink G.D., MohanKumar S.M., MohanKumar P.S. Chronic estradiol-17beta exposure increases superoxide production in the rostral ventrolateral medulla and causes hypertension: reversal by resveratrol. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300:R1560-R1568.
318. Wang Z., Huang Y., Zou J., Cao K., Xu Y., Wu J.M. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int. J. Mol. Med. 2002, 9:77-79.
319. Turrens J.F., Lariccia J., Nair M.G. Resveratrol has no effect on lipoprotein profile and does not prevent peroxidation of serum lipids in normal rats. Free Radic. Res. 1997, 27:557-562.
320. Wilson T., Knight T.J., Beitz D.C., Lewis D.S., Engen R.L. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci. 1996, 59:L15-L21.
321. Babacanoglu C., Yildirim N., Sadi G., Pektas M.B., Akar F. Resveratrol prevents high-fructose corn syrup-induced vascular insulin resistance and dysfunction in rats. Food Chem. Toxicol. 2013, 60:160-167.
322. Crandall J.P., Oram V., Trandafirescu G., Reid M., Kishore P., Hawkins M., Cohen H.W., Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67:1307-1312.
323. Wong R.H., Howe P.R., Buckley J.D., Coates A.M., Kunz I., Berry N.M. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis. 2011, 21:851-856.